Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 15, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments including:
•Awarded ISO 13485 Certification for Excellagen, State of California manufacturing license and state clearances to market and sell Excellagen in the U.S., and advanced other international registrations for Excellagen, including CE Mark registration, which the Company expects to receive approval on or around the end of the second quarter 2013.
Help employers find you! Check out all the jobs and post your resume.
